Economic news

Lilly to Buy Calytrix for Up to $1.5B in Blood Cancer Bet

Nov 16 (Reuters) - Eli Lilly has agreed to acquire privately held biotech Calytrix Bio for up to $1.5 billion in cash, ​as it looks to expand the development of treatments for ‌rare blood cancers.

The move, announced on Monday by Calytrix, is the latest in a string of acquisitions by the Indianapolis-based pharmaceutical giant as it works to ​diversify beyond its blockbuster diabetes and weight-loss franchise.

Lilly shares were ​up 1.4% in early trading.

The deal is expected to strengthen ⁠Lilly's footprint in hematology, by adding an experimental treatment to a ​business that already includes the FDA-approved blood cancer medicine Jaypirca. It ​also follows Lilly's $2.3 billion acquisition of Ajax Therapeutics earlier this year, another bet on the blood cancer space.

The latest transaction includes an upfront payment and additional payments tied ​to clinical trial and regulatory milestones, Calytrix said. It did not ​disclose the size of the upfront payment or when the deal is expected to ‌close.

Calytrix's ⁠lead candidate is an early-stage antibody treatment for essential thrombocythemia and myelofibrosis – rare blood disorders that cause the bone marrow to produce excessive abnormal blood cells. The drug has not yet entered human clinical trials.

The ​treatment targets mutated ​calreticulin, a ⁠genetic alteration that drives disease in patients with the blood disorders. Calytrix said it is designed to attack ​abnormal cells driving the illness while leaving healthy ​blood-forming cells ⁠intact.

Current treatments manage symptoms and reduce complications rather than directly target the underlying disease-causing cells, according to the company.

Calytrix, based in Wellesley Hills, Massachusetts, ⁠was ​founded by J.P. Morgan Life Sciences Private ​Capital, the venture capital arm within J.P. Morgan Asset Management. Its investors include Westlake BioPartners ​and Avoro Ventures.

Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shailesh Kuber

Source: Reuters


To leave a comment you must or Join us


More news


Back to economic news list

By visiting our website and services, you agree to the conditions of use of cookies. Learn more
I agree